The advent of biomarker testing has brought targeted cancer treatment to more patients than ever before. However, these tests require a collaborative effort from a number of specialists—and that means a high price tag. Additionally, private payers have different reimbursement structures that change frequently, resulting in lengthy pre-authorization periods.
On this episode of CANCER BUZZ, we speak to two financial navigators about their roles helping patients and providers understand the options available to patients in need of biomarker testing.
Guests:
Related Content:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.
